CG
ZVRA icon

Cutler Group’s Zevra Therapeutics ZVRA Stock Holding History

Cutler Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$1K – 4871
2022
Q4 		$1K Sell
200
-1,400
-88% -$7.11K ﹤0.01% 4207
2022
Q3 		$19K Hold
1,600
– – ﹤0.01% 2671
2022
Q2 		$22K Sell
1,600
-200
-11% -$912 ﹤0.01% 2609
2022
Q1 		$21K Sell
1,800
-400
-18% -$2.54K ﹤0.01% 3042
2021
Q4 		$20K Sell
2,200
-400
-15% -$3.57K ﹤0.01% 3139
2021
Q3 		$20K Sell
2,600
-400
-13% -$4.03K ﹤0.01% 3359
2021
Q2 		$20K Sell
3,000
-7,900
-72% -$84.9K ﹤0.01% 3313
2021
Q1 		$13K Buy
+10,900
New +$95.2K ﹤0.01% 3600

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Cutler Group's ZVRA Position: Q1 2023 in Review

Cutler Group sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 679 shares — an estimated $3K sold.

Cutler Group first reported a position in ZVRA in Q2 2016 and held it in 10 quarters. The position peaked at $119K in Q1 2021. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

  • Cutler Group reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 679 Zevra Therapeutics shares in Q1 2023, an estimated $3K.
  • Cutler Group first reported a position in Zevra Therapeutics in Q2 2016 and held it in 10 quarters.
  • Cutler Group's Zevra Therapeutics position peaked at $119K in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.